The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 6th 2025
A rehabilitation method commonly used in patients who experience a traumatic brain injury was found to improve symptoms of long COVID, including brain fog and measures of daily living.
Drug Interactions Are Biggest Barrier in Patients With HIV and Cancer
November 21st 2016Much research and literature has been devoted to cardiovascular diseases, neurocognitive diseases, and neuroendocrine dysfunction in the aging patient with HIV, but cancer in patients with HIV is also a growing concern.
Read More
Shorter Courses of Antibiotics May Sometimes Be Better in the Long Run
November 18th 2016For many years, prescribers have instructed patients to finish their entire course of antibiotics even after they start feeling better. However, recent study results have shown that longer durations of antibiotics are not always beneficial.
Read More
Janssen and Onyx Collaborate to Study Darzalex for Cancer Treatment
November 17th 2016Janssen has entered a clinical trial collaboration and supply agreement with Onyx to evaluate the efficacy and safety of Darzalex, the first-in-class CD38-directed immunotherapy daratumumab, in combination with a proteasome inhibitor carfilzomib and dexamethasone.
Read More
Considerations in Expanded Buprenorphine Access for Opioid Abuse Disorder
November 17th 2016Buprenorphine is one of the most commonly prescribed medications to treat opioid addiction. In 2014, about 60-65% of Americans using medication-assisted treatment received buprenorphine. On July 6, 2016, the Department of Health and Human Services (HHS) announced that it will raise the limit on the number of patients that can receive the addiction medicine buprenorphine to 275 patients per qualified provider. This article describes potential monetary conflicts in proving buprenorphine, how increased access will affect pharmacists and what they can do to help patients in need of medication supported abstinence and substance abuse counseling.
Read More
Baricitinib Shows Early Response, Improved Patient-Reported Outcomes in Rheumatoid Arthritis
November 16th 2016A post-hoc analysis of a pair of phase 3 trials evaluating baricitinib in patients with rheumatoid arthritis (RA) showed significant improvement in patient-reported outcomes compared with placebo and adalimumab (Humira).
Read More